C4 Therapeutics (CCCC) Enterprise Value (2019 - 2026)
C4 Therapeutics' quarterly Enterprise Value came in at -$235.7 million in Q1 2026, down 9.57% year-on-year from -$260.6 million in Q1 2025, and up 5.18% quarter-over-quarter from -$248.5 million in Q4 2025.
C4 Therapeutics has reported Enterprise Value for 8 years, with the latest figure at -$235.7 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 9.57% year-over-year to -$235.7 million; the trailing twelve-month figure through Mar 2026 stood at -$235.7 million (down 9.57% YoY), and the FY2025 full-year result was -$248.5 million, down 1.48% from the prior year.
- Enterprise Value for Q1 2026 stood at -$235.7 million, up from -$248.5 million in the prior quarter.
- The five-year high for Enterprise Value was -$191.9 million in Q3 2025, with the low at -$313.7 million in Q3 2022.
- Average Enterprise Value over 5 years is -$254.4 million, with a median of -$255.6 million recorded in 2024.
- Year-over-year, Enterprise Value surged 33.94% in 2022 and retreated 18.04% in 2024.
- Tracing CCCC's Enterprise Value over 5 years: stood at -$276.2 million in 2022, then rose by 8.14% to -$253.7 million in 2023, then rose by 3.46% to -$244.9 million in 2024, then slipped by 1.48% to -$248.5 million in 2025, then climbed by 5.18% to -$235.7 million in 2026.
- The last three Enterprise Value figures came in at -$235.7 million (Q1 2026), -$248.5 million (Q4 2025), and -$191.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -235.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -235.67 Mn |
| Dec 31, 2025 | -248.54 Mn |
| Sep 30, 2025 | -191.88 Mn |
| Jun 30, 2025 | -214.55 Mn |
| Mar 31, 2025 | -215.09 Mn |
| Dec 31, 2024 | -244.90 Mn |
| Sep 30, 2024 | -255.64 Mn |
| Jun 30, 2024 | -264.10 Mn |
| Mar 31, 2024 | -258.19 Mn |
| Dec 31, 2023 | -253.68 Mn |
| Sep 30, 2023 | -216.57 Mn |
| Jun 30, 2023 | -267.29 Mn |
| Mar 31, 2023 | -270.33 Mn |
| Dec 31, 2022 | -276.15 Mn |
| Sep 30, 2022 | -313.65 Mn |
| Jun 30, 2022 | -307.78 Mn |
| Mar 31, 2022 | -291.17 Mn |
| Dec 31, 2021 | -309.28 Mn |
| Sep 30, 2021 | -402.07 Mn |
| Jun 30, 2021 | -465.91 Mn |
| Mar 31, 2021 | -313.48 Mn |
| Dec 31, 2020 | -371.69 Mn |
| Sep 30, 2020 | -199.41 Mn |
| Jun 30, 2020 | -107.65 Mn |
| Mar 31, 2020 | -73.86 Mn |
| Dec 31, 2019 | -90.55 Mn |
| Sep 30, 2019 | -100.97 Mn |